Therefore, further mechanistic studies of PSGL-1 and VISTA in myeloid cells and T cells could uncover novel therapeutic targets for enhancing immune function (e.g., in cancer) or suppressing immune responses (e.g., in autoimmune diseases and transplant rejection) Fig. 2. This evidence concerns the gene SELPLG and cancer.